Acelrx pharmaceuticals announces publication of results from an investigator-initiated trial on sufentanil sublingual tablet (sst) compared to standard intravenous opioids during plastic surgery procedures performed under general anesthesia

Study found that sst lowered the opioid dose required by patients in the post-anesthesia care unit (pacu) by more than five-fold compared to standard intravenous opioid administration hayward, calif. , may 10, 2022 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of clinical data from an investigator-initiated trial in patients undergoing lengthy plastic surgery procedures performed under general anesthesia, where use of a single sufentanil sublingual tablet 30 mcg (sst; dsuvia®) in conjunction with intravenous (iv) opioids was able to dramatically reduce postoperative opioid requirements compared to an equivalent dose of opioids administered only via the iv route.
ACRX Ratings Summary
ACRX Quant Ranking